MX2014000066A - Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. - Google Patents

Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.

Info

Publication number
MX2014000066A
MX2014000066A MX2014000066A MX2014000066A MX2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A MX 2014000066 A MX2014000066 A MX 2014000066A
Authority
MX
Mexico
Prior art keywords
gel formulations
based gel
bacterial vaginosis
high dosage
treat bacterial
Prior art date
Application number
MX2014000066A
Other languages
English (en)
Inventor
Michael T Nordsiek
Kodumudi S Balaji
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47391265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014000066(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of MX2014000066A publication Critical patent/MX2014000066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

La presente descripción proporciona formulaciones de gel mucoadhesivo de base acuosa de metronidazol útiles para una variedad de propósitos, incluyendo la aplicación intravaginal como un abordaje terapéutico para el tratamiento de individuos que padecen y/o a los que se les diagnosticó vaginosis bacteriana.8.
MX2014000066A 2011-06-28 2012-06-28 Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana. MX2014000066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502285P 2011-06-28 2011-06-28
US201161508058P 2011-07-14 2011-07-14
PCT/US2012/044738 WO2013003646A1 (en) 2011-06-28 2012-06-28 High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis

Publications (1)

Publication Number Publication Date
MX2014000066A true MX2014000066A (es) 2014-05-01

Family

ID=47391265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000066A MX2014000066A (es) 2011-06-28 2012-06-28 Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.

Country Status (9)

Country Link
US (4) US8946276B2 (es)
EP (1) EP2725904A4 (es)
JP (2) JP5986632B2 (es)
CN (2) CN107823123A (es)
AU (2) AU2012275292B2 (es)
BR (1) BR112013033759B1 (es)
CA (2) CA3054236A1 (es)
MX (1) MX2014000066A (es)
WO (1) WO2013003646A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408243VA (en) 2012-06-13 2015-01-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
EP3013368A1 (en) 2013-06-25 2016-05-04 Mission Pharmacal Company Novel formulations for the treatment of vaginal disorders
US11337989B2 (en) 2013-12-19 2022-05-24 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
WO2016196653A1 (en) 2015-06-01 2016-12-08 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
EP3522879A4 (en) * 2016-10-04 2020-06-03 Evofem, Inc. METHOD OF TREATING AND PREVENTING BACTERIAL VAGINOSIS
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO1988006888A1 (en) 1987-03-20 1988-09-22 Curatek Pharmaceuticals, Inc. Novel topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
DE69201547T2 (de) 1991-10-18 1995-08-03 Dow Corning Silikon druckempfindliche Klebstoffe mit verbesserter Haftung an Substraten mit niedriger Oberflächenspannung.
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
WO1998014768A2 (en) 1997-10-06 1998-04-09 Schwartz Sorell L Transdermal chemical monitoring device
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US7368122B1 (en) 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7645803B2 (en) 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US7456207B2 (en) 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2887149B1 (fr) 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
FR2882552B1 (fr) 2005-02-25 2008-12-26 Galderma Sa Gel aqueux de haute stabilite a base de metronidazole et procedes pour leur preparation
EP1919449A2 (en) 2005-06-07 2008-05-14 Foamix Ltd. Antibiotic kit and composition and uses thereof
FR2890559B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour la preparation
FR2890560B1 (fr) 2005-09-13 2011-06-24 Galderma Sa Mousses dermatologiques a base de metronidazole et emulsions pour leur preparation
AU2006336612A1 (en) 2005-11-09 2007-08-02 Dow Pharmaceutical Sciences Azithromycin for treatment of granulomatous rosacea
BRPI0620908A2 (pt) 2006-01-05 2011-11-29 Drugtech Corp composição farmacêutica, sistema de distribuição antibacteriana e antifúngica vaginal e uso da composição farmacêutica
FR2899475A1 (fr) 2006-04-10 2007-10-12 Galderma Res & Dev Composition pharmaceutique pour le traitement de la rosacee
WO2008038140A2 (en) 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
US20080287513A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287515A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287514A1 (en) 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
US7893097B2 (en) 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20100105750A1 (en) 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US9629856B2 (en) 2010-03-03 2017-04-25 Anteis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds

Also Published As

Publication number Publication date
BR112013033759A2 (pt) 2016-08-16
JP6235087B2 (ja) 2017-11-22
US9198858B2 (en) 2015-12-01
EP2725904A4 (en) 2014-12-10
US20160106714A1 (en) 2016-04-21
US20130005785A1 (en) 2013-01-03
BR112013033759B1 (pt) 2021-05-25
JP2017014248A (ja) 2017-01-19
CN103763925A (zh) 2014-04-30
CA2840571A1 (en) 2013-01-03
AU2016200825A1 (en) 2016-03-03
CA3054236A1 (en) 2013-01-03
US8946276B2 (en) 2015-02-03
US20190183859A1 (en) 2019-06-20
US10596155B2 (en) 2020-03-24
AU2012275292A1 (en) 2014-01-23
WO2013003646A1 (en) 2013-01-03
AU2016200825B2 (en) 2017-10-26
CA2840571C (en) 2020-03-24
US10238634B2 (en) 2019-03-26
JP5986632B2 (ja) 2016-09-06
EP2725904A1 (en) 2014-05-07
US20130005787A1 (en) 2013-01-03
AU2012275292B2 (en) 2015-11-12
BR112013033759A8 (pt) 2018-07-31
CN107823123A (zh) 2018-03-23
JP2014518272A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
AU2011328009A8 (en) Compounds and methods for treating pain
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MY158992A (en) Forms of rifaximin and uses thereof
IN2015DN01156A (es)
WO2015009726A3 (en) Medical uses of cd38 agonists
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MY165086A (en) Formulations of rifaximin and uses thereof
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2014006686A (es) Derivaods novedosos de pirrol.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
EA201390925A1 (ru) Производные санглиферина и способы их получения
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MY166463A (en) Positive allosteric modulators of nicotinic acetylcholine receptor
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
UA71871U (ru) Способ диагностики эффективности антибиотикотерапии у больных лайм-борелиозом